Bibliografia

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints:preferred definitions and conceptual framework. Clin PharmTher 2001; 69: 89-95.
2. Gøtzsche PC, Torri ALV, Rossetti L. Beware of surrogate outcome measures. Int J Technol Assess Health Care 1996; 12: 238-46.
3. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-5.
4. Wier CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006; 25: 183-203.
5. www.consort-statement.org/
6. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:60513.
7. www.gimbenews.it/, luglio-agosto 2009, vol 2 num 6
8. Howe et al. Exercise for preventing and treating osteoporosis in postmenopausal women. The Cochrane Collaboration 2011.